Navigation Links
Dendreon Corp. (Nasdaq: DNDN) - Prostate Cancer Patients Benefit
Date:4/30/2009

VALLEY COTTAGE, N.Y., April 30 /PRNewswire/ -- Less than two weeks ago, early on April 15th, Stock Preacher, in their Stock Talk section, posted a Special Technical Report on Dendreon Corporation (Nasdaq: DNDN), which we have been watching since 2007, when we first learned about it.

On April 14, DNDN gapped open on positive news from the previous day's close of 7.30/shr, to 16.00/shr, ran to 22.00/shr and closed at 16.99/shr + 9.69 (132%) on 65,345,600/shrs on the day, and since has traded as high as 27.00/shr over the past several trading sessions. From a technical POV, DNDN has traded down to close the gap it posted on the opening on April 14. This is very positive and Bullish action.

When we go back to look at the Stock Talk coverage, the Red Roadmaster's analysis after the April 14, 2009 market action was overall Bullish: in the near term Very Bullish, mid-term Bullish, and long term Bullish.

That analysis has proven to be true and the shares are having a dramatic run here, with overhead resistance Nil, and strong underlying support 21.40.

Yesterday,(April 29, 2009) DNDN closed + 11.13/shr (95%) at 23.00 on 48,134,768/shrs., the high on the day was 27.00/.

Late Tuesday afternoon, the Company released data from a Phase III clinical study that showed Provenge extended the lives of men with advanced prostate cancer by an average of 4.1 months. According to published analysts, Dendreon should be able to file for regulatory approval during the Q-4 Y 2009, with possible approval during the first half of 2010.

This is Dendreon Corp (DNDN): Dendreon is developing therapeutic vaccines that boost the body's immune system to help it fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. Its lead candidate is Provenge, a therapeutic vaccine that targets prostate cancer. Dendreon is also working on a therapeutic vaccine called Neuvenge as a treatment for breast, colon, ovarian, and kidney cancers; and it has research programs investigating cancer-fighting monoclonal antibodies and small molecule drugs. Its partners for its antibody programs include Amgen and Genentech

For more updates on Dendreon Corp (Nasdaq: DNDN), and other Companies making news, visit us at http://StockPreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a wholly owned entity of Allan James Group, Inc., a financial public relations firm. Please read our report and visit our website, StockPreacher.com, for complete risks and disclosures.

Investors can view all of the daily updates for free by visiting: http://StockPreacher.com/

Julio Serrano of Stock Preacher is a member of the National Association of Securities Dealers, CRD number 1603068.


'/>"/>
SOURCE Stock Preacher
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. -Dendreon to Hold Conference Call on Thursday, November 15, 2007 at 4:30 PM ET-
2. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
3. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
4. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
5. Drug Detection Kits Manufactured By IDenta Corp. Shown During French Television Broadcast (at TF1) - Product Aids French Police In Bust of 600 Kilograms Of Cocaine
6. ComPsych(R) Corp. Announces Health at Work(SM) Award Winners: Sprint, Erie Insurance, City of Naperville and Green Hills Public Library
7. New Health Corp. Announces the Addition of Hannaford Bros., Kash N Karry and Sweet Bay Supermarkets to its Retail Outlets
8. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
9. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
10. Former State Representative Terry Parke Joins Secure Services Corp.
11. InstaCare Corp. Reviewing M&A Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process Analytics is ... plant water and steam. , Chlorides and sulfates cause pitting and stress corrosion ... maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels has therefore ...
(Date:3/28/2017)... Los Angeles, CA (PRWEB) , ... March 28, ... ... Pediatrics credential, which will be offered by the American Association of Integrative Medicine ... Saturday presentations for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. ...
(Date:3/28/2017)... ... 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader ... women’s hair loss. Although hair transplant procedures can be seen as more of a ... can be two reasons a woman may see her hair thinning. , “We are ...
(Date:3/28/2017)... ... ... are probably not the first ingredients that come to mind when thinking about healthy food. ... can actually improve health outcomes. And the good news is they may be hiding in ... peer-reviewed paper led by Maria Marco, Ph.D. , University of California, Davis and ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Drs. Justin Kolnick, ... Week by teaching their patients about the key role this treatment plays in protecting ... an experienced endodontist. To better serve those who need a root canal in White ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... that the European Medicines Agency (EMA) has notified ... 30 mcg) Marketing Authorisation Application (MAA) has passed ... MAA is underway. The MAA for ARX-04 (known ...
(Date:3/28/2017)... SAN FRANCISCO , March 28, 2017 ... is expected to reach USD 8.0 billion by 2025, ... Inc. The increasing incidence of infectious diseases and cancer ... for use in disease diagnosis over the coming years. ... the usage of autologous and allogenic stem cell therapy, ...
(Date:3/27/2017)... 2017 Summary This report ... and its partnering interests and activities since 2010. Description ... in-depth insight into the partnering activity of one of the ... reports are prepared upon purchase to ensure inclusion of the ... The report will be delivered in PDF format within 1 ...
Breaking Medicine Technology: